Combine Abbott's diverse business portfolio with a steady drumbeat of new product approvals and what do you get? A solid full-year financial performance and momentum going forward. Demonstrating this, Abbott significantly exceeded the earnings per share (EPS) guidance it provided at the start of 2022. Contributing to this success was strong performance across multiple businesses during the fourth quarter as the pandemic continued to ease. This growth includes sales of established pharmaceuticals, up 7.9% organic* (1.0% reported) and medical devices, up 7.4% organic (flat on a reported basis). Here are the key numbers. For the quarter: $10.1 billion in worldwide sales $1.03 adjusted diluted EPS from continuing operations1 For the full year: $43.7 billion in worldwide sales, up 6.4% organic (1.3% reported) $5.34 adjusted diluted EPS from continuing operations2 Abbott issued full-year guidance for 2023 adjusted diluted EPS from continuing operations of $4.30 to $4.50.3 These are the key fourth-quarter highlights: Sales of FreeStyle Libre systems exceeded $1 billion with U.S. sales growing more than 40%. Highly productive R&D pipeline that continues to strengthen the company's medical devices portfolio with recent advancements and milestones, including: U.S. Food and Drug Administration approval of Eterna spinal cord stimulation system, the smallest implantable, rechargeable system currently available to treat chronic pain.4,5 Recognition of Abbott’s FreeStyle Libre systems as the 'Best Medical Technology' of the last 50 years by the Galien Foundation. And just recently, Abbott received FDA approval for Navitor, the company's latest-generation transcatheter aortic valve implantation (TAVI) system designed to help open a narrowed aortic valve in people with severe aortic stenosis. For full financials and reconciliation of non-GAAP measures, you can read Abbott's press release. For further information, take a look at a summary of Abbott's earnings highlights and download it here.